Cargando…
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
The biological agents approved for the treatment of patients with metastatic colorectal cancer – bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A, along with cetuximab and panitumumab, two monoclonal antibodies that target the epidermal growth factor receptor – ar...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425342/ https://www.ncbi.nlm.nih.gov/pubmed/22930641 http://dx.doi.org/10.2147/OTT.S31412 |